All In Biotech

Drug Trial Radar · NCT04812262

A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DD01 in Overweight/Obese Subjects With T2DM and NAFLD

Last checked: Nov 19, 2026Latest source record: Apr 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 255 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

255

Actual

Start

Feb 24, 2021

Primary completion

Dec 20, 2022

Study completion Feb 14, 2023

Sponsor

Lead sponsor
Neuraly, Inc.Industry
Sponsor type
Industry
First posted
Mar 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, first in human (FiH), randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to investigate the safety, tolerability, PK and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD). The study will be conducted in 2 Parts (Part A and B), with up to 8 cohorts included in each part (Part A; Cohorts A1 to A8 and Part B; Cohorts B2 to B8).

Conditions

  • Overweight and Obesity
  • Type2 Diabetes
  • NAFLD

Interventions

  • DD01Drug

    The active of DD01 is a synthetic peptide, administered in a 1mL volume for injection.

  • PlaceboDrug

    Placebo drug of DD01, administered in a 1mL volume for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events and serious adverse eventsTime frame: Part A - 43 days
  2. Number of participants with treatment-related adverse events and serious adverse events (TEAEs)Time frame: Part B - 57 days
  3. Number of participants with clinically significant abnormalities in clinical laboratory valuesTime frame: Part A - 43 days
  4. Number of participants with clinically significant abnormalities in clinical laboratory valuesTime frame: Part B - 57 days
  5. Number of participants with clinically significant abnormalities in physical examinationsTime frame: Part A - 43 days
  6. Number of participants with clinically significant abnormalities in physical examinationsTime frame: Part B - 57 days
  7. Number of participants with clinically significant abnormalities in vital signsTime frame: Part A - 43 days
  8. Number of participants with clinically significant abnormalities in vital signsTime frame: Part B - 57 days
  9. Blood Pressure assessed by 24-hour ambulatory blood pressure monitoring (ABPM)Time frame: Part A - 43 days
  10. Blood Pressure assessed by 24-hour ambulatory blood pressure monitoring (ABPM)Time frame: Part B - 57 days
  11. Heart Rate assessed by 24-hour ambulatory electrocardiography monitoring reader)Time frame: Part A - 43 days
  12. Heart Rate assessed by 24-hour ambulatory electrocardiography monitoring reader)Time frame: Part B - 57 days
  13. Number of participants with clinically significant abnormalities in 12-lead ECGsTime frame: Part A - 43 days
  14. Number of participants with clinically significant abnormalities in 12-lead ECGsTime frame: Part B - 57 days

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Prosciento

    Chula Vista, California

  • Southwest General Healthcare Center

    Fort Myers, Florida

  • Combined Research Orlando

    Orlando, Florida

  • FDI Clinical Research

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.